Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699613 | 0.88 | MDM2 (0.41) | MDM2DRD2DRD4CYP3A4 | |
| SCHEMBL13699600 | 0.88 | MDM2 (0.39) | MDM2DRD2DRD4ADAMTS5MMP2 | |
| SCHEMBL13699588 | 0.87 | MDM2 (0.41) | MDM2DRD2DRD4CYP3A4 | |
| SCHEMBL13699578 | 0.85 | MLNR (0.44) | DRD2DRD4CYP3A4NOTUM | |
| SCHEMBL13699611 | 0.83 | MLNR (0.36) | MDM2CYP3A4 | |
| SCHEMBL13699576 | 0.81 | RIPK1 (0.39) | MDM2DRD2DRD4ADAMTS5MMP2 | |
| SCHEMBL13699577 | 0.81 | RIPK1 (0.39) | MDM2DRD2DRD4ADAMTS5MMP2 | |
| SCHEMBL13699575 | 0.79 | RIPK1 (0.41) | MDM2DRD2DRD4ADAMTS5MMP2 | |
| SCHEMBL13699557 | 0.79 | AKR1C3 (0.50) | NOTUM | |
| SCHEMBL13699605 | 0.78 | CXCR4 (0.42) | MDM2DRD2DRD4RIPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885DRD2 290/4885DRD4 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.